Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Reports $2.6M in Revenues for Q1

NEW YORK, April 30 - Compugen today reported revenues of $2.6 million and a net loss of $2.3 million for the first quarter ending March 31.


Revenues, which included $455,000 from R&D grants, were down from the $2.8 million for the year-ago quarter, The Tel Aviv, Israel-based firm said. Net loss, including a non-cash charge of $94,000 for amortization of deferred compensation, dropped from the year-ago quarter's loss of $3.2 million. The company reported R&D expenses of   $3.2 million for the quarter, compared to $3.4 million for the same quarter in 2002.


The company reported $67.3 million in cash, cash equivalents and securities on hand as of March 32, comparable to the year-ago quarter and including a $1.7 million private placement by its ag-bio subsidiary Evogen.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.